Antibodies
19 March 2010
Anti-Cancer Agents, Herceptin and Xeloda17 March 2010
HUMAN GENOME SCIENCES ANNOUNCES RESULTS OF RANDOMIZED PHASE 2 TRIAL OF MAPATUMUMAB IN NON-SMALL CELL LUNG CANCER17 March 2010
CytoDyn Begins Full Humanization of Cytolin16 March 2010
4-Antibody Announces a Long-Term Collaboration With Boehringer Ingelheim for Therapeutic Antibodies16 March 2010
Single Short Course of Tolerx’s Otelixizumab Provides Prolonged Preservation of Beta Cell Function15 March 2010
Innate Immune, Inc. Enters into a License and Commercialization Agreement with Cephalon Australia Pty Ltd12 March 2010
Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer11 March 2010
BioInvent and Human Genome Sciences Announce Collaboration to Co-develop and Commercialize Therapeutic Antibodies8 March 2010
Genmab Announces Results from Zalutumumab Phase III Study of Refractory Head and Neck Cancer Patients4 March 2010
CSL Behring Receives FDA Approval of Hizentra, First 20 Percent Subcutaneous Immunoglobulin Therapy1 March 2010
arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies24 February 2010
Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System’s Ability to Destroy Anthrax Bacteria24 February 2010
Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer22 February 2010
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint18 February 2010
VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular EdemaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports